Back to News
Market Impact: 0.3
Novo partners with Anthropic to speed up drug development with Claude
Source: reuters.com
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Novo Nordisk partnered with Anthropic to deploy Claude AI models in accelerating the discovery and development of new medicines. The collaboration could improve R&D productivity and reinforce Novo Nordisk's use of AI in drug development, though no financial terms or timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVO0.55
More News
- H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end
- 'Hostile act': Trump threatens EU with tariffs over Canada associate-membership proposal
- US official says upcoming spectrum auctions could generate more than $100 billion
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- Fed delivers its first hike in 3 years. Plus, what's moving Starbucks and GE Vernova
- Fed’s Warsh lays out forces driving up bond yields
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Analyze SEC Filings With AI: A Verification-First Guide
- AI for IR Street Intelligence: Notes, Estimates, and Peers